Better medication guidance for older adults with chronic kidney disease
(R01) Strengthening the Evidence-Base to Support Medication Prescribing in Older Adults with Chronic Kidney Disease
This project looks at how common heart and diabetes medicines affect health and kidney function in adults aged 65 and older with chronic kidney disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11264792 on NIH RePORTER |
What this research studies
This project will look at medical records from the national Veterans Affairs system and a large electronic health record database to see how older adults with chronic kidney disease fared after starting common heart and diabetes medicines. Researchers will compare outcomes for people who start ACE inhibitors versus other blood-pressure drugs and SGLT2 inhibitors versus other glucose-lowering medicines, and will also examine newer cardiovascular drugs. They will measure long-term kidney function, heart-related events, and medication-related harms in real-world patients. Findings from the VA will be checked against another large EHR dataset to make sure results hold up across health systems.
Who could benefit from this research
Good fit: Adults aged 65 or older with chronic kidney disease, particularly those with diabetes or taking blood-pressure, heart, or glucose-lowering medicines, are the primary group this research focuses on.
Not a fit: People younger than 65, those without chronic kidney disease, or patients on dialysis or with a kidney transplant are unlikely to benefit directly from this project's findings.
Why it matters
Potential benefit: If successful, this work could help doctors choose safer, more effective medications for older adults with CKD and reduce medication-related harms.
How similar studies have performed: Randomized trials have shown benefits for some ACE inhibitors and SGLT2 inhibitors, but older adults with CKD were often left out of those trials, so using large real-world databases to answer these questions is a relatively new approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Dave, Chintan — Rutgers Biomedical and Health Sciences
- Study coordinator: Dave, Chintan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.